



SEVEN YEARS OF CRYO-BALLOON CATHETER ABLATION. FOLLOW-UP ANALYSIS, RESULTS, RECURRENCES, COMPLICATIONS AND SIDE EFFECTS IN PATIENTS TREATED FOR **PAROXYSMAL ATRIAL FIBRILLATION**, WITH A PROSPECTIVE PROTOCOL GUIDED BY COMPLETE BIDIRECTIONAL LEFT ATRIUM-PULMONARY VEINS DISCONNECTION AFTER ADENOSINE AS MAIN TARGET END POINT. A **SINGLE CENTER REPORT**.

Jesus M. Paylos , C. Ferrero , L. Azcona, A. Morales, M. A. Vargas, L. Lacal, C.M. Cilleros, T.G. Delange.

Arrhythmia Unit and Electrophysiology Lab.

Moncloa University Hospital

European University of Madrid

Madrid (Spain)

Disclosure None Conflict Of Interest







Complete pulmonary veins isolation (**PVI**) from the **left atrium** (**LA**) is **CRUCIAL** to cure patients with **A**trial Fibrillation.



INTRODUCTION



PVI with Cryo-Balloon (CB) has demonstrated it's effectiveness for the treatment of Paroxysmal Atrial Fibrillation (PAF).



INTRODUCTION



However, Cryo-Energy **CB** application **doesn't produce a homogeneous circumferential lesion** (*) in all **PV**, wich is related to their anatomical shape and size.

(*) Paylos J.M. et.al. "Gadolinium Delayed-Enhancement MRI to asses the extension of residual cryo-balloon catheter induced lesion at the Left-Atrium-PV-Junction level in patients treated for Paroxismal Atrial Fibrillation". Heart Rhythm Vol. 7. No.5 May Supplement 2010.



INTRODUCTION



And a better cuantification of the **Cryoablation zone** and the anatomical extent of pulmonar vein have been better clarify in recent years(*).

(*) Chierchia G.B. et.al. "Anatomical extent of pulmonary vein isolation after cryoballon ablation for atrial Fibrillation: Comparison between the 23 and 28mm balloons". J. Cardiovasc Med (Hagerstown) 2011 ; 12:840-84.
(*) Kenigsberg D.N. et. al. "Quantification of the cryoablation zone demarcated by pre- and postprocedural electroanatomic mapping in patients with atrial fibrillation using the 28-mm second-generation cryoballoon". Heart Rhythm. 2015;12 No2: 282-290



INTRODUCTION



Incomplete lesions with **dormant tissue** (despite a "perfect" occlusion) can occur leading to a **residual conduction (RC) gaps** causing (or responsible) for PV reconduction wich is the principal cause of **RECURRENCE**.



INTRODUCTION



- Adenosine (AD) has been used to "unmask" RC in apparently isolated PV with Radiofrequency (RF).
- Routine use of **AD** after acute **CB-PVI** allows to identify incomplete lesions with **dormant tissue** not evident in basal conditions.
- Focal/ Freeze/RF applications eliminates such RC.



INTRODUCTION



The Only "**No Evidence**" of **PV**/Electrical activity on the "circular-mapping-catheter" at the **LA-PV Junction** level after **CB-PVI** is "**Not Enough**" to assure "complete **acute PVI**", and checking for **Entry** and **Exit** Block is Mandatory to **confirm it**.



INTRODUCTION



We analyzed our **seven years** follow-up experience of our patients, initially treated with **CB** for **PAF**, with demonstration of complete bidirectional electrical isolation (**CBEI**) of the pulmonary veins (**PV**) from the left atrium (**LA**) after **AD** as the main target end point to achieve, in all cases.



INTRODUCTION (Protocol)



- Exit block
 - By pacing PV from all 20 poles of the circular catheter at high amplitude voltage with consistent 1:1 PV capture and no evidence at all of Any atrial response.
- Entry block
 - By pacing LA from the CS-Catheter at three different cycle lengths (600, 500, 400 mS) with consistent 1:1 LA capture and no evidence at all of Any PV electrical activity in any of the 20 poles of circular-catheter mapping placed into the vein at the LA-PV Junction level.



METHODS



- With this approach:
 - Checking for **Entry** and **Exit** / Block.
 - After Basal / Acute **PVI**, and **repeating** / After **AD**.
 - Elimination of "Residual gaps" by Freeze/Focal RF / Applications.
- Since November 2008 to July 2015:



• Highgly **symptomatic**, suffering from **recurrent PAF**, **refractory** to medical **treatment**, were **treated** with the **"CB"** and **Followed-Up**







- 114 Patients (mean age 56±13 years).
 86 Male (75.4%) mean age 53 ± 13
 - 28 Female (24.6%) mean age 61 ±10
- ✓ Mean / Years / PAF: 5 ±5 (1-25)
- ✓ Folow-up time / Days: 1693 ±653 (90-2520)
- ✓ Mean / Episodes PAF / Year: 58±66 (2-200)

✓ None Structural Heart Disease.

Mean LVEF: 67 ±5 %.



METHODS



• All patients previously treated with antiarrhythmic: ✓ ßß (87%)

- ✓ Class III (1.7%)
- ✓ Class 1C (89.5%)
- ✓ ßß + 1C (76.3%).








Morphological and structural data:


LA Diameters (mm)	LA/ AREA (cm²)	PV (mm) 434	CT 22	LVEF
AP:37±6 (21-50)		AP:18±5 (8-32)	AP: 26±6 (18-35)	
LAT : 47±7 (35-61)	22±4 (11-32)	SI:20±4 (10-28)	SI : 26±5 (17-31)	67±5 % (59-79)
SI: 54±7 (40-75)				



METHODS







* In 1 patient 28mm CB was used (Proximal application) & 23mm CB (Distal application).




METHODS




PV CARTOGRAPHY / MAPPING

• **Circular** Duodecapolar 7 French with adjustable diameter catheter. (Saint Jude Reflexion Spiral).

Grade(*) of CB / Application / Occlusion / for PVI






(*) Neumann T, et. al. "Circumferential pulmonary vein isolation with the cryoballoon technique results from a prospective 3-center study". J Am Coll Cardiol. 2008;52:273-8.







Cryo-Ablation (Mean Temperature Reached)









Adenosine / Protocol

- **Bolus** administration of increasing doses (12-18-24... mgrs).
 - Pacing PV / LA (600, 500, 400 mS CL).

•WHEN

• A-V Conduction Block Ocurred.



METHODS



Freeze/ RF protocol

- Residual Conduction gaps (RC)
 - Basal
 - After checking (Basal) for Entry and Exit Block
 - After checking (Adenosine) for Entry and Exit Block

Were eliminated by Freeze/Focal RF Applications.

- •Only the most Extensive **RC** required ≥2 **RF Focal** Applications to **Abolished.**
 - RC >2 Pair / Electrode / Circular Catheter
 Repeated
 New CB / Application (Occlusion)



RESULTS



A total of **434 PV** and **22 Common Trunks (CT)** were **treated** with **CB**

CBEI demonstrated in 392 (90.3%). Acute reconduction post CB showed 42 (9%) PV.

14 (3,2%) Residual Conduction (gap). **16 (3,5%) /392 PV R**econduction after **Adenosine**.

patients

12 (2,7%) Extrapulmonary Muscular Connections (EMC)(*) 9 patients


(*) Cabrera J.A. Ho S.Y., Climent V. et al, "Morphological evidence of muscular connections between contiguous pulmonary venous orifices: Relevance of the interpulmonary isthmus for Catheter ablation in Atrial Fibrillation" Heart Rhythm 2009;6:1192-1198 (*) Squara F., Liuba L, Chik W. et al. "Electrical connection between ipsilateral pulmonary veins: Prevalence and implications for ablation and adenosine testing" Heart Rhythm 2015;12:275-282.




METHODS




Oclussion Degree III with contrast / Leakage



RF/RSPV gap




gap After Adenosine






METHODS LIPV/Basal






Oclussion Degree IV / LIPV






LIPV Post-Crio








CHE 10-20

METHODS



Pacing (Circular 1,2) PV Exit Block



Adenosine 12 mg. i.v. RC / gap / Pacing (Circular 1,2) Conduction 1:1 PV/LA




METHODS




RF/Residual Potential/gap



Adenosine 12 mg. i.v. Pacing gap / RF Catheter Conduction 1:1 PV/LA



RF/Residual Potential/gap









• BB after Adenosine 422/434 PV

96.5 %

• The Remaining 12/434 PV

Extrapulmonary Muscular Connection

Were Demonstrated and All finally abolished by Focal RF applications distal into the vein.





METHODS




EXTRAPULMONARY MUSCULAR CONNECTION


Pacing Proximal Antrum (Circular 13-14) Exit Block





Pacing Distal Vein (Circular 13-14) Conduction 1:1 PV/LA









METHODS



EXTRAPULMONARY MUSCULAR CONNECTION Pacing gap Distal Vein / RF Catheter Conduction 1:1 PV/LA








Pacing Distal / Post Focal RF

Exit Block





RESULTS **FOLLOW-UP**




- First / **3 months / after CB** / ablation
- All patients were under medical treatment, including:
 Flecainide
 - Atenolol
 - Oral Anticoagulation (Dicumarine)
- •And completely / stopped and **discontinued** / After this period.





RESULTS **FOLLOW-UP**





Early Recurrences.

•Occurred when medication stopped after three months blanking-period in **9 male**.

Late Recurrences.

• Presented **3 male** at **24**, **27** and **60 months** and **2 female** at **7** and **40 months** respectively.







• 14 Patients out of 114 RECURRED.

12.3 %

Second procedure (REDO)










RECURRENCES


• **REDO** Cases (Second Procedure) 14 patients with 54 PV. Including 2 CT.

















•We have not done any protocol to rule out **Non PV-Foci** (as a potential cause of Arrhythmia recurrence)*, because all recurrences were **REDO**, and **PV-LA reconduction** demonstrated in **all cases**.

(*) Hayashi K, An Y, Nagashima M. et. al. "Importance of nonpulmonary vein foci in catheter ablation for paroxysmal atrial fibrillation". Heart Rhythm 2015;12:1918-1924



RESULTS



In a **REDO** follow-up (40±14 months) **All 14** pts remain in **Sinus Rhythm with not medication**.

• The REMAINING 100 Patients Follow-up 1693±653 days (3-84 months)

87.7 %

• Are Asymptomatic, Free of Drugs, in Sinus Rhythm.




RESULTS



•SIDE EFFECTS AND COMPLICATIONS:

- ✓ Aphonia(*): 6 pts (5.7%).
- ✓ Phrenic paresia(**): 7 (6.7%).
- ✓ Phrenic palsy(**): 2 (1.9%).
- ✓ Pulmonary infiltrates*: 5 (4.8%).
- ✓ Dyspepsia: **2** (1.9%).
- ✓ Bronchospasm: 2 (1.9%).
- ✓ Intra-nodal reentry: **2** (1.9%).
- ✓ In-hospital arrhythmia: **1** (0.9%).

* Pulmonary infiltrates



(*) Cabrera J.A., Murillo M, Climent V. et. al. "Relationship between the left Recurrent Lariyngeal nerve and left atrium: A postmortem study in patients with and without Atrial Fibrillation". Heart Rhythm. 2011;S413: PO5-152. (**) Mugnai G. De Asmundis C, Ciconte G. et. al. "Incididence and Characteristics of complications in the setting of second-generation cryoballoon ablation: A large single-center study of 500 consecutive patients". Heart Rhythm. 2015;12:1476-1482..







SIDE EFFECTS AND COMPLICATIONS

RSPV – **CB** application.

TRANSIENT PHRENIC NERVE PARESIA						
	T ºC	Seconds	CB mm.	CB Generation		
1	-68	122	28	FIRST		
2	-73	222	28	FIRST		
3	-55	89	28	SECOND		
4	-56	165	23	SECOND		
5	-60	115	28	SECOND		
6	-68	100	28	SECOND		
7	-65	190	28	SECOND		
PERMANENT PHRENIC NERVE PALSY						
1	-70	100	28	FIRST		
2	-68	156	28	FIRST		

78% an T.ºC≥







SIDE EFFECTS AND COMPLICATIONS

Follow-up.

- **Aphonia:** Lasting \leq 72 hours.
- **Permanent Phrenic Nerve Palsy**: Chest X-Ray (1-3 years)
- **Pulmonary Infiltrates:** (No Symptoms). Showed at first month CT-Scan control. No evidence at 3 months CT-Scan control.
- **Dyspepsia:** Quick complete resolution ≤ 72 hours (Omeprazol).







SIDE EFFECTS AND COMPLICATIONS

Mortality	0
Atrioesophageal fistula	0
PV Stenosis	0







1. Cryo-Energy PV application **doesn't produce a homogeneus circumferential lesion in all PV**.

2. Checking for **BB** and **Adenosine** protocol allow to identify **19%** of patients with potential substrate for **PV/ LA** Reconduction and possibly recurrence of the Arrhythmia.

3. Routine use of AD after acute **CB-PVI** allows to identify incomplete lesions with **dormant tissue**, and eliminate them by **freeze** or **focal RF** applications, **Improves** the long-term rate of the **"possible"** definitive **cure** of patients suffering **PAF**.



CONCLUSIONS



4. **CB** technique **alone** is very **effective** and **safe** for the definitive treatment of **PAF**, with 68.7% success rate, increasing up to **87.7%** when this protocol is applied, remaining Patients in sinus rhythm, **free of arrhythmia**, without medication, in a very **long-term followup**.



CONCLUSIONS



5. However, **Late Recurrences**, generates some concern about a greater increase number of patients with recurrent arrhythmia in a longer term, **specially in the future patients who don't feel symptoms of the arrhythmia**







"To the best of our Knowlegde... This serie includes the largest follow-up described, so far".